nintedanib esylate: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target

nintedanib esylate‘s R&D Progress

Nintedanib esylate is a small molecule drug that targets several receptors including CSF-1R, FGFRs, FLT3, PDGFR, and VEGFR. It has been approved for use in various therapeutic areas including respiratory diseases, neoplasms, urogenital diseases, eye diseases, and skin and musculoskeletal diseases.

The drug has shown efficacy in treating several indications, including scleroderma, systemic, Hamman-Rich Syndrome, lung diseases, interstitial, systemic sclerosis-associated interstitial lung disease, non-small cell lung cancer, idiopathic pulmonary fibrosis, pterygium, renal cell carcinoma, and progressive fibrotic interstitial lung disease.

Nintedanib esylate was developed by Boehringer Ingelheim International GmbH and received its first approval in the United States in October 2014. It has since been approved in other countries as well, making it a globally recognized drug.

In terms of regulatory status, Nintedanib esylate has undergone special review projects and has been designated as an orphan drug. It has also received priority review, fast track, and breakthrough therapy designations, indicating its potential to address unmet medical needs and expedite its development and approval process.

Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

Mechanism of Action for nintedanib esylate: CSF-1R antagonists FGFRs antagonists FLT3 inhibitors PDGFR inhibitors VEGFR antagonists

CSF-1R antagonists are drugs that specifically target and inhibit the activity of the Colony-Stimulating Factor 1 Receptor (CSF-1R). CSF-1R is a protein receptor found on the surface of certain cells, including immune cells and cancer cells. By blocking the interaction between CSF-1R and its ligands, CSF-1R antagonists can interfere with the signaling pathways that promote cell growth, survival, and immune suppression. These antagonists have shown potential in the treatment of various diseases, including cancer, by inhibiting tumor growth and enhancing anti-tumor immune responses.

FGFRs antagonists refer to drugs that act as antagonists or inhibitors of the Fibroblast Growth Factor Receptors (FGFRs). FGFRs are a family of cell surface receptors involved in various cellular processes, including cell growth, differentiation, and angiogenesis. By blocking the activation of FGFRs, these antagonists can disrupt the signaling pathways associated with abnormal cell growth and proliferation, making them potential therapeutic agents for cancer treatment.

FLT3 inhibitors are a class of drugs that target and inhibit the activity of the Fms-Like Tyrosine Kinase 3 (FLT3) receptor. FLT3 is a protein receptor found on the surface of certain blood cells, particularly hematopoietic stem cells and myeloid progenitor cells. Abnormal activation of FLT3 is associated with the development and progression of certain types of leukemia. FLT3 inhibitors work by blocking the activity of FLT3, thereby inhibiting the growth and survival of leukemia cells.

PDGFR inhibitors are drugs that specifically target and inhibit the activity of the Platelet-Derived Growth Factor Receptors (PDGFRs). PDGFRs are cell surface receptors involved in cell growth, proliferation, and tissue repair. Abnormal activation of PDGFRs is associated with various diseases, including certain types of cancer and fibrotic disorders. PDGFR inhibitors can block the signaling pathways mediated by PDGFRs, thereby inhibiting cell growth and reducing the proliferation of cancer cells or fibrotic tissue.

VEGFR antagonists are drugs that act as antagonists or inhibitors of the Vascular Endothelial Growth Factor Receptors (VEGFRs). VEGFRs are cell surface receptors involved in angiogenesis, the formation of new blood vessels. By inhibiting the activation of VEGFRs, these antagonists can disrupt the signaling pathways that promote the growth and development of blood vessels. This can be beneficial in the treatment of diseases such as cancer, where angiogenesis plays a critical role in tumor growth and metastasis. VEGFR antagonists are commonly used as anti-angiogenic therapies in cancer treatment.

Drug Target R&D Trends for nintedanib esylate

CSF-1R, FGFRs, FLT3, PDGFR, and VEGFR are crucial receptors involved in various physiological processes in the human body. CSF-1R plays a vital role in regulating the development and function of macrophages, which are essential for immune response and tissue homeostasis. FGFRs are involved in cell growth, differentiation, and tissue repair. FLT3 is a receptor found on hematopoietic stem cells and is crucial for the development of blood cells. PDGFR is involved in cell proliferation and migration, particularly in connective tissues. VEGFR plays a key role in angiogenesis, the formation of new blood vessels. Understanding the functions of these receptors is crucial for developing targeted therapies in the pharmaceutical industry.

According to Patsnap Synapse, as of 6 Sep 2023, there are a total of 1 CSF-1R + FGFRs + FLT3 + PDGFR + VEGFR drugs worldwide, from 10 organizations, covering 18 indications, and conducting 259 clinical trials.

Based on the analysis of the provided data, the current competitive landscape of the target CSF-1R + FGFRs + FLT3 + PDGFR + VEGFR indicates that C.H. Boehringer Sohn AG & Co. KG, Cloudbreak Therapeutics Ltd., and Cloudbreak Therapeutics LLC are the companies growing fastest. The highest stage of development is seen in C.H. Boehringer Sohn AG & Co. KG, with drugs in various phases. The approved indications for this target include Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial, Scleroderma, Systemic, Non-Small Cell Lung Cancer, systemic sclerosis-associated interstitial lung disease, and Hamman-Rich Syndrome. Small molecule drugs are progressing rapidly, with one in the approved phase and one in the inactive phase. The countries/locations developing fastest under this target include the European Union, United States, China, and Japan, with progress also seen in other countries such as Poland, United Kingdom, Australia, Hungary, Ukraine, South Africa, India, Sweden, Chile, Czechia, Finland, Germany, Norway, Turkey, Denmark, and Greece. The progress in China is particularly noteworthy. Overall, the target CSF-1R + FGFRs + FLT3 + PDGFR + VEGFR shows a promising competitive landscape and potential for future development in the pharmaceutical industry.

Please click on the picture link below for free registration or log in directly if you have a freemium account, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target

Conclusion

Overall, Nintedanib esylate is a small molecule drug that targets multiple receptors and has been approved for use in various therapeutic areas. Its approval in the United States in 2014 marked a significant milestone, and it has since gained recognition globally. The drug’s regulatory status and designations highlight its potential as a breakthrough therapy for multiple indications.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart